A Phase 1, Open-Label, Randomized, Parallel Group Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Vedolizumab Administered in Prefilled Syringe Versus Prefilled Syringe in Needle Safety Device in Healthy Subjects
Latest Information Update: 14 Aug 2019
At a glance
- Drugs Vedolizumab (Primary)
- Indications Coeliac disease; Crohn's disease; Graft-versus-host disease; Malignant melanoma; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 16 May 2019 New trial record